decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Drugs / Compliance Tips and Tools / OIG_Doctors need to watch for wily drug marketers
Subscribe or sign in to view the full article.
Article Overview
This piece explains how certain pharmaceutical marketing tactics can create compliance risk for physicians and other providers who order, administer, or bill for drugs. It focuses on general categories of concern discussed in OIG-related guidance and testimony, including gifts, consulting arrangements, off-label promotion issues, pricing strategies, and the downstream effects of investigations and exclusion actions. The article is relevant to healthcare compliance staff, physicians, and providers who want a high-level understanding of drug-marketing pitfalls and why they matter.
Why This Topic Matters
Drug marketing practices can expose providers to billing, fraud-and-abuse, and exclusion risk even when they are not the primary target of an investigation. Understanding the broad compliance issues helps providers recognize when to slow down, ask questions, and review company practices before they become a problem.
Article Sections
-
Compliance concerns in pharmaceutical marketing
Introduces the compliance context for physician interactions with drug company representatives and discusses why these interactions can attract government attention.
-
Warning signs in drug company practices
Covers several broad categories of marketing behavior discussed in the article, including gifts, consulting relationships, off-label promotion, and pricing-related tactics.
-
OIG compliance guidance and provider awareness
Summarizes the article’s closing emphasis on using compliance resources and recognizing when additional scrutiny may be warranted.
What You Will Learn
- How pharmaceutical marketing can create compliance risk for providers
- Why certain drug company practices may attract OIG attention
- What broad categories of conduct are highlighted as caution areas
- How compliance resources can help providers understand acceptable and risky interactions
Who Should Read This
- Physicians
- Healthcare compliance officers
- Billing and reimbursement staff
- Medical practice administrators
- Drug administration providers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com